Dalnacogene Ponparvovec

波哌达可基

Report date: 2026/03/26 14:46:50

Base Information

Drug NameDalnacogene Ponparvovec
Drug Alias Name信玖凝BBM-H901
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV843 vector
Mechanisms of ActionCoagulation factor IX stimulants
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsHemophilia B
Approved Indications in ChinaHemophilia B
Original Approved Country/TerritoryMainland China
Original Approved Date2025/04/08
Country/TerritoryMacauMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBelef BioMed (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBelief BioMed IncTakeda Pharmaceutical Co LtdShanghai Belief-Delivery BioMed Co Ltd
Inactive CompaniesShanghai Mianyi Biotechnology Co LtdInstitute Of Hematology & Blood Diseases Hospital
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A